Angioedema, Hereditary, Types I and II
Conditions
Keywords
KVD824, KOMPLETE
Brief summary
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
Interventions
DRUGKVD824
KVD824 300 mg Modified-Release Tablets
Placebo to KVD824 300 mg Modified-Release Tablets
Sponsors
KalVista Pharmaceuticals, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects 18 years of age and older. 2. Confirmed diagnosis of HAE type I or II at any time in the medical history: 1. Documented clinical history consistent with HAE (subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria) AND EITHER 2. Diagnostic testing results obtained prior to randomization that confirm HAE Type I or II: C1-INH functional level \<40% of the normal level. Subjects with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. Testing may be obtained from central or local laboratories or obtained from documented historical testing results. Subjects may be restested at anytime prior to randomization if results are incongruent with clinical history or believed by the Investigator to be confounded by recent prophylactic or therapeutic C1 INH use, OR 3. Documented genetic results that confirm known mutations for HAE Type I or II. 3. Subject has access to and ability to use conventional treatment for HAE attacks. 4. Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk. 5. Subject's last dose of attenuated androgens was at least 28 days prior to first dose of IMP. 6. During the Run-in Period subject meets one of the following criteria: 1. Two Investigator-confirmed attacks in the first 4-week period. 2. Three Investigator-confirmed attacks in ≤8 weeks. 7. Subjects who are fertile and heterosexually active must adhere to contraception requirements throughout the trial as follows: a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include: i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4). ii) Intrauterine device (IUD). iii) Intrauterine hormone-releasing system (IUS). iv) Bilateral tubal occlusion. v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of surgical success). b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of investigational medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner. 8. Subjects who are not fertile or not sexually active, as defined below, do not require contraception. 1. Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject. 2. Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success). 3. Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post menopausal for at least 12 months. 9. Subjects must be able to swallow trial tablets whole. 10. Subjects assessed by the Investigator must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary. 11. Investigator believes that the subject is willing and able to adhere to all protocol requirements. 12. Subject provides signed informed consent and is willing and capable of complying with trial requirements and procedures.
Exclusion criteria
1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria. 2. A clinically significant history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator. 3. Use of angiotensin converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization. 4. Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization. 5. Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported by OAT1, OCT2, and OATP1B1, starting at screening, as determined by the Investigator. 6. Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit. Note: These medications include but are not limited to the following: Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole. Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort. 7. Inadequate organ function, including but not limited to; 1. Alanine aminotransferase (ALT) \> 2x Upper limit of Normal (ULN). 2. Aspartate aminotransferase (AST) \> 2x ULN. 3. Bilirubin direct \> 1.25x ULN. 4. International normalized ratio (INR) \> 1.2. 5. Clinically significant hepatic impairment defined as a Child-Pugh B or C. 6. Estimated glomerular filtration rate (eGFR) \<60 mL/min. 8. Any clinically significant comorbidity or systemic dysfunction that in the opinion of the Investigator would jeopardize the safety of the subject by participating in the trial. 9. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator. 10. Known hypersensitivity to KVD824 or placebo or to any of the excipients. 11. Any prior use of any gene therapy treatment for HAE. 12. Participation in any interventional investigational clinical trial, including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening. 13. Any pregnant or breastfeeding subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Rate of Investigator-confirmed HAE Attacks During the Treatment Period | 12 weeks | To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period. | 12 weeks | Logistic regression on subjects were measured without investigator-confirmed HAE Attacks (FAS). Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
| Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period. | 12 weeks | A summary of negative binomial regression on investigator-confirmed HAE attacks with conventional treatment is presented for the FAS. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
| Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline) | 12 weeks | AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
| Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline). | 12 weeks | AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
| Proportion of Subjects With an AECT Score ≥12 at the End of the Treatment Period. | 12 weeks | AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements. |
Countries
Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, New Zealand, North Macedonia, Puerto Rico, United Kingdom, United States
Contacts
STUDY_DIRECTORStudy Director
KalVista Pharmaceuticals
Participant flow
Recruitment details
Recruitment Start Date - 06Aug21-27Oct22 First Patient Enrolled - 18Nov21 Long term follow-up planned: No Independent data monitoring committee (IDMC) involvement: No
Pre-assignment details
Screening details- Screening included the screening visit and run-in period. After screening, subjects entered run-in period of upto 8wks.Start of the run-in period was determined by type of HAE therapy being used by the subject at the time of screening. Period 1 or Treatment period (overall period)- Randomized-controlled and double blind 33 subjects assigned treatment: 29 received and included in safety and efficacy analysis; 4 did not receive IMP as study was terminated before 1st dose.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants |
| Age, Continuous | 53.0 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment Australia | 0 participants |
| Region of Enrollment Bulgaria | 0 participants |
| Region of Enrollment Czechia | 1 participants |
| Region of Enrollment France | 2 participants |
| Region of Enrollment Germany | 0 participants |
| Region of Enrollment Hungary | 1 participants |
| Region of Enrollment Italy | 1 participants |
| Region of Enrollment North Macedonia | 2 participants |
| Region of Enrollment Puerto Rico | 0 participants |
| Region of Enrollment United Kingdom | 0 participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 8 | 0 / 7 | 0 / 7 |
| other Total, other adverse events | 5 / 7 | 6 / 8 | 6 / 7 | 1 / 7 |
| serious Total, serious adverse events | 1 / 7 | 1 / 8 | 2 / 7 | 0 / 7 |
Outcome results
None listed